Seeking Alpha

FDA AdComm meeting over Novartis' Serelaxin

  • An FDA advisory committee is meeting to discuss whether to approve Novartis' (NVS) Serelaxin treatment for acute heart failure.
  • On Tuesday, FDA staff recommended that the agency not approve Serelaxin.
  • You can watch the AdComm here.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: